1. Tuberculosis in the United States
National Surveillance System
Highlights from 2002
Division of Tuberculosis Elimination
Centers for Disease Control and Prevention

2. Reported TB Cases United States, 1982-2002
No. of Cases
1982
1986
1990
1994
1998
2002
Year

3. TB Morbidity United States, 1998-2002
Year Cases Rate* , , , , ,
*Cases per 100,000

4. TB Case Rates, United States, 2002
D.C.
< 3.5 (year 2000 target)
> 5.2 (national average)
Rate: cases per 100,000

5. TB Case Rates by Age Group United States, 1992-2002
Cases per 100,000
Age Group (years)

6. Reported TB Cases by Age Group United States, 2002
<15 yrs (6%)
65+ yrs
(21%)
15-24 yrs (10%)
25-44 yrs
(35%)
45-64 yrs
(28%)

7. TB Case Rates by Age Group and Sex, United States, 2002
Cases per 100,000

8. TB Case Rates by Race/Ethnicity United States, 1992-2002
Cases per 100,000
Asian/Pacific Islander
American Indian/Alaska Native
Black, non-Hispanic
White, non-Hispanic
Hispanic

9. Reported TB Cases by Race/Ethnicity United States, 2002
White, non-Hispanic
(20%)
Hispanic
(27%)
American Indian/
Alaska Native (1%)
Asian/Pacific Islander
(22%)
Black, non-Hispanic
(30%)

10. TB Case Rates by Age Group and Race/Ethnicity, United States, 2002
Cases per 100,000
Age Group (yrs)
American Indian/Alaska Native
Asian/Pacific Islander
Black, non-Hispanic
Hispanic
White, non-Hispanic

11. Number of TB Cases in U. S. -born vs
Number of TB Cases in U.S.-born vs. Foreign-born Persons United States,
No. of Cases

12. Trends in TB Cases in Foreign-born Persons, United States, 1986-2002
No. of Cases
Percentage

13. Percentage of TB Cases Among Foreign-born Persons United States
1992
2002
>50%
25%-49%
<25%

14. TB Case Rates in U. S. -born vs
TB Case Rates in U.S.-born vs. Foreign-born Persons, United States,
Cases per 100,000

15. TB Case Rates in U. S. -born vs
TB Case Rates in U.S.-born vs. Foreign-born Persons, United States,
Cases per 100,000

16. Countries of Birth for Foreign-born Persons Reported with TB United States, 2002
Other
Countries
(38%)
Mexico
(25%)
Philippines
(11%)
S. Korea
(3%)
Vietnam
(8%)
Haiti
(3%)
India
(7%)
China
(5%)

17. Length of U.S. Residence Prior to TB Diagnosis, United States, 2002

18. Primary Anti-TB Drug Resistance United States, 1993-2002
% Resistant
Note: Based on initial isolates from persons with no prior history of TB.
MDR TB defined as resistance to at least isoniazid and rifampin.

19. Primary MDR TB United States, 1993-2002
No. of Cases
Percentage
Note: Based on initial isolates from persons with no prior history of TB.
MDR TB defined as resistance to at least isoniazid and rifampin.

20. Primary Isoniazid Resistance in U. S. -born vs
Primary Isoniazid Resistance in U.S.-born vs. Foreign-born Persons United States,
Percentage
Note: Based on initial isolates from persons with no prior history of TB.

21. Primary MDR TB in U. S. -born vs
Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States,
% Resistant
Note: Based on initial isolates from persons with no prior history of TB.
MDR TB defined as resistance to at least isoniazid and rifampin.

22. Completeness of HIV Test Results in Persons with TB by Age Group United States, 1993-2001
% with Test Results
Note: Includes cases with positive, negative, or indeterminate HIV test results and cases from California in persons reported with AIDS.
(HIV test results are not reported from California.) All 2001 cases from California have an unknown HIV status.

23. Estimated HIV Coinfection in Persons Reported with TB United States, 1993-2001
Note: Minimum estimates based on reported HIV-positive status
among all TB cases in the age group. All 2001 cases from California have an unknown HIV status.

24. Mode of Treatment Administration in Persons Reported with TB United States, 1993-2000
Directly observed therapy (DOT); Self-administered therapy (SA)

25. Completion of TB Therapy United States, 1993-2000*
Percentage
*Healthy People 2010 target: Completed in 1 yr or less
Note: Persons with initial isolate resistant to rifampin and children under years old with meningeal, bone or joint, or miliary disease excluded.